Next-Generation CGM System
Continuous Glucose Monitoring for Diabetes
Research & DevelopmentEarly-stage Development
Key Facts
Indication
Continuous Glucose Monitoring for Diabetes
Phase
Research & Development
Status
Early-stage Development
Company
About Senseonics
Senseonics Holdings, Inc. is a commercial-stage medical device company with a mission to revolutionize diabetes care via its long-term, implantable CGM platform. Its flagship Eversense system, approved for 180-day wear in the US and 365-day wear in Europe, represents a significant technological differentiation in a market dominated by short-term, transcutaneous sensors. The company's strategy hinges on leveraging its proprietary fluorescent sensor technology and a global commercialization partnership with Ascensia Diabetes Care to capture market share in the multi-billion-dollar CGM landscape.
View full company profileTherapeutic Areas
Other Continuous Glucose Monitoring for Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Eversense E3 / XL (180-day) | Senseonics | FDA PMA Approved |
| Eversense 365-day System | Senseonics | CE Mark Approved |